QED Therapeutics is developing precision medicine therapies targeting FGFR-driven skeletal dysplasias, including achondroplasia and hypochondroplasia. Their investigational drug, Infigratinib, is the first therapy for achondroplasia to receive FDA breakthrough therapy designation, aiming to provide effective treatment options for affected individuals.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Skeletal dysplasias, such as achondroplasia and hypochondroplasia, are genetic disorders that affect bone and cartilage growth, leading to significant physical challenges. Current treatment options are limited, and there is a need for therapies that directly address the underlying molecular mechanisms driving these conditions.
Solution
QED Therapeutics is focused on developing precision medicine therapies for FGFR-driven skeletal dysplasias. Their lead investigational drug, Infigratinib, targets the fibroblast growth factor receptor (FGFR) pathway, which plays a crucial role in bone development. By selectively inhibiting FGFR, Infigratinib aims to modulate skeletal growth and improve outcomes for individuals with achondroplasia and hypochondroplasia. The company's research and development efforts are centered on providing effective treatment options that address the root causes of these disorders.
Target Audience
The primary target audience includes individuals diagnosed with FGFR-driven skeletal dysplasias, such as achondroplasia and hypochondroplasia, and the healthcare professionals who treat them.
Features
- Infigratinib: a selective FGFR inhibitor specifically designed for skeletal dysplasias
- Clinical trials focused on achondroplasia and hypochondroplasia
- FDA breakthrough therapy designation for Infigratinib in achondroplasia
- Observational studies to further understand the natural history of hypochondroplasia